About CANBRIDGE-B Company

Founded in 2012, Beihai Kangcheng is a leading global biopharmaceutical company focused on rare diseases based in China, dedicated to researching, developing and commercializing transformative therapies. We are led by an experienced management team with extensive industry experience in rare fields, spanning research and development, clinical development, regulatory affairs, business development, and commercialization through June 21, 2021. Backed by a talent pool of 151 employees, 22 of whom have doctorates. and/or M.D., a multinational biopharmaceutical company where more than 80% of our employees have worked, our management team shares a record of successfully commercializing rare disease treatments in major markets (including China, the US, Europe, Latin America, and Southeast Asia). Using the expertise of our management, we are advancing the rare disease industry and shaping China's rare disease ecosystem. For example, our founder, Dr. Xue, is currently the Vice Chairman of the China Rare Disease Alliance (CHARD). As of June 21, 2021, we have built a comprehensive and differentiated pipeline of 13 drug assets with huge market potential, targeting some of the most common rare diseases and rare tumor indications, including 3 marketed products, 3 drug candidates in the clinical stage, 2 in the IND activation stage, 2 in the pre-clinical stage, and 3 other gene therapy projects in the pilot identification stage. In the field of rare diseases, we have seven biologics and small molecule products and candidates for the treatment of Hunter syndrome (MPS II) and other lysosomal storage disorders (LSD), complement-mediated diseases, hemophilia A, metabolic diseases, and rare liver cholestasis including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Among them, we obtained listing approval for Hunterase (CAN101) for MPS II in mainland China in September 2020. We initiated a phase 1 clinical trial of CAN106 in Singaporean health volunteers, and received an IND acceptance letter from the National Drug Administration for the CAN106 phase 1 study in April 2021. In the rare field of oncology, we are developing CAN008 to treat glioblastoma multiforme (GBM). As of June 21, 2021, the other two oncology products, CaphosolTM (CAN002) and Nerlynx (CAN030), have also been approved for marketing in mainland China and Greater China, respectively. In addition to biologics and small molecules, we are also investing in the next generation of gene therapy technology. We are developing two gene therapy products using AAV SL65 capsid carriers licensed from LogicBio Therapeutics to treat Fabry disease and Pompeii disease, with the option to use the same carrier to develop two additional indications and clinical-stage gene editing procedures for treatment of methylmalonic acidemia (MMA) in accordance with our partnership agreement with LogicBio Therapeutics. We are also collaborating with our research partner UMass to sponsor research programs to develop gene therapy solutions for neuromuscular diseases and exclusively select assets to license for development. Additionally, we are internally developing adeno-associated virus (AAV) delivery platforms for different tissues, such as the central nervous system (CNS) and muscle.